Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease

This study is currently recruiting participants.
Verified June 2011 by Phelps, Kenneth R., M.D.
Sponsor:
Information provided by:
Phelps, Kenneth R., M.D.
ClinicalTrials.gov Identifier:
NCT01191762
First received: August 27, 2010
Last updated: June 17, 2011
Last verified: June 2011

August 27, 2010
June 17, 2011
April 2010
August 2012   (final data collection date for primary outcome measure)
Fractional reduction in [PTH] in CKD after a 4-week course of sevelamer carbonate [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01191762 on ClinicalTrials.gov Archive Site
Correlation of [PTH] to phosphate excretion per volume of glomerular filtrate [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease
The Effect of Sevelamer Carbonate on Critical Variables in the Pathogenesis of Secondary Hyperparathyroidism

The hypothesis underlying this study is that phosphate interferes with PTH-mediated calcium reabsorption in the distal nephron and thereby necessitates supranormal [PTH]to maintain normocalcemia in chronic kidney disease. This study will examine the hypothesis with measures of phosphate homeostasis and calcium reabsorption. A double-blind trial of the intestinal phosphate binder sevelamer carbonate will be employed to examine whether reductions in phosphate influx alter distal nephron phosphate concentration and the [PTH] required for calcium reabsorption in the expected manner.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Hyperparathyroidism
  • Chronic Kidney Disease
  • Drug: sevelamer carbonate
    2400 mg with each meal for 4 weeks
    Other Name: sevelamer carbonate = Renvela (Genzyme)
  • Drug: placebo
    3 tablets with each meal
  • Active Comparator: sevelamer carbonate
    2400 mg (3 pills) with each meal
    Intervention: Drug: sevelamer carbonate
  • Placebo Comparator: placebo control
    3 placebo tablets with each meal; tablets are identical to sevelamer carbonate 800 mg tablets.
    Intervention: Drug: placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
30
August 2012
August 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • eGFR < 60 ml/min
  • age at least 18 years

Exclusion Criteria:

  • any primary parathyroid disease
Both
18 Years and older
Yes
Contact: Kenneth R. Phelps, M.D. 518-626-6415 kenneth.phelps@va.gov
Contact: Deborah Hallenbeck, RN,MSN 518-626-6419 deborah.hallenbeck@va.gov
United States
 
NCT01191762
PhelpsK
No
Kenneth R. Phelps, M.D.
Phelps, Kenneth R., M.D.
Not Provided
Principal Investigator: Kenneth R. Phelps, M.D. Stratton VAMC, Albany, NY
Phelps, Kenneth R., M.D.
June 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP